Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ETX-929
- Development stage
- Preclinical
- Lead developer
- ENSEM Therapeutics
- Modality
- Small Molecules
01
Overview
ETX-929 is a small-molecule pan-KRAS inhibitor being developed by ENSEM Therapeutics. It is designed to target a broad spectrum of KRAS mutations, specifically including G12X, G13X, and Q61H variants, as well as KRAS wildtype amplified tumors. By inhibiting the active state of the KRAS protein, ETX-929 aims to disrupt oncogenic signaling pathways, such as the MAPK/ERK pathway, which drive tumor growth and survival. This pan-KRAS approach is intended to provide a therapeutic option for patients with various KRAS-driven solid tumors, including those not addressed by current allele-specific inhibitors (such as G12C-specific agents).
02
Targets
Beyond the preview
Go deeper on ETX-929.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ETX-929.